- Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
- Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
- Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
- Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
- Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
- Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
- Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
- Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
- Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
- Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
More ▼
Key statistics
On Thursday, Tiziana Life Sciences Ltd (TLSA:NAQ) closed at 0.454, 10.19% above the 52 week low of 0.412 set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.42 |
---|---|
High | 0.46 |
Low | 0.4182 |
Bid | 0.421 |
Offer | 0.455 |
Previous close | 0.417 |
Average volume | 50.40k |
---|---|
Shares outstanding | 102.27m |
Free float | 57.82m |
P/E (TTM) | -- |
Market cap | 46.43m USD |
EPS (TTM) | -0.1496 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 19:58 BST.
More ▼